CLOTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLOTIC (CLOTIC).
Clotrimazole is an imidazole antifungal that inhibits ergosterol synthesis by inhibiting 14α-demethylase (CYP51), leading to disruption of fungal cell membrane integrity and increased permeability.
| Metabolism | Clotrimazole is primarily metabolized in the liver via oxidation and glucuronidation. Minor metabolism by CYP3A4; most of the drug is excreted as metabolites in bile and feces. |
| Excretion | Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as inactive conjugates. |
| Half-life | Terminal elimination half-life is 3.5 hours (range 2.5-4.5 h) in adults with normal renal function; extends to 6-8 hours in mild-moderate renal impairment. |
| Protein binding | 92-96% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd is 0.5-0.7 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral: 85-90% (first-pass metabolism minimal); Topical: 5-10% systemically absorbed. |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes; Topical: 1-2 hours. |
| Duration of Action | Oral: 6-8 hours; IV: 6-8 hours; Topical: 12-24 hours depending on formulation. |
Topical: Apply a thin layer to affected areas 2-4 times daily. Duration limited to 2 weeks; maximum 50 g/week. Intralesional: 0.5-1 mL of 10 mg/mL solution injected into lesion weekly.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific dose adjustment required for topical or intralesional use. Systemic absorption is negligible; no GFR-based modifications. |
| Liver impairment | No dose adjustment necessary for topical or intralesional administration. No Child-Pugh based modifications. |
| Pediatric use | Topical: Apply sparingly once or twice daily. Limit to small areas; avoid prolonged use. Intralesional: Not recommended; alternative agents preferred. |
| Geriatric use | Use caution due to thinner skin; apply sparingly and limit duration. Monitor for skin atrophy and systemic effects. No specific dose reduction but avoid excessive use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLOTIC (CLOTIC).
| Breastfeeding | Clotrimazole is poorly absorbed systemically after topical application. No data on excretion into breast milk are available; however, due to minimal systemic absorption, the risk to the nursing infant is expected to be negligible. The M/P ratio is unknown. |
| Teratogenic Risk | Clotrimazole (CLOTIC) is classified as FDA Pregnancy Category B. In animal studies, no teratogenic effects were observed at doses up to 100 mg/kg/day. However, human data are limited. First trimester exposure is not associated with increased risk of major birth defects. No specific fetal risks have been identified for second or third trimester use. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to clotrimazole or any component of the formulation","Not for use in eyes or for ophthalmic infections","First trimester of pregnancy (topical use is generally avoided, though systemic absorption is minimal)"]
| Precautions | ["Hypersensitivity reactions (contact dermatitis, urticaria)","Hepatic impairment (caution with systemic use, but topical application has minimal absorption)","Avoid contact with eyes","Not for ophthalmic use","May cause local irritation or burning sensation","Immunocompromised patients may require longer treatment"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond standard prenatal care. If used for extended periods on large areas of skin, monitor for local irritation or hypersensitivity. |
| Fertility Effects | Clotrimazole has no known adverse effects on fertility. Animal studies showed no impairment of fertility at doses up to 100 mg/kg/day. |